Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Raissa Quezado Da Nobrega

Pain Medicine Washington, DC Medical Doctor

NPI 1629500582 CMS profile 11300164

2150 Pennsylvania Ave Nw Fl 7, Washington, DC 20037

Open in the dashboard

General payments

$15,816

50 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Raissa Quezado Da Nobrega of Washington, DC is reported in the CMS Open Payments database as having received $15,816 across 50 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25 1
2024 General $209 3
2023 General $402 6
2022 General $4,711 32
2021 General $10,468 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raissa Quezado Da Nobrega
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Raissa Quezado Da Nobrega were reported at $25. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Raissa Quezado Da Nobrega Pain Medicine median Middle half National median
2019 $0 $498 $126–$1,682 $163
2020 $0 $284 $80–$910 $114
2021 $10,468 $399 $112–$1,219 $132
2022 $4,711 $455 $137–$1,484 $149
2023 $402 $484 $128–$1,495 $160
2024 $209 $498 $131–$1,540 $164
2025 $25 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $10,322 7 payments
  2. Abbott Laboratories $4,763 34 payments
  3. SPR Therapeutics, Inc $193 2 payments
  4. Nalu Medical, Inc. $147 1 payment
  5. Boston Scientific Corporation $122 1 payment
  6. Saluda Medical Americas, Inc. $106 1 payment
  7. Nevro Corp. $74 1 payment
  8. Stratus Medical, LLC $44 1 payment
  9. Merck Sharp & Dohme Corporation $25 1 payment
  10. AbbVie, Inc. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Grant $10,000 1 payment
  2. Food and Beverage $2,933 40 payments
  3. Travel and Lodging $2,883 9 payments
Products named General payments · program years 2021–2025
  1. SYNCHROMED $10,033 2 payments
  2. PROCLAIM Neuromodulation $2,375 19 payments
  3. PROCLAIM Neuromodulation $2,103 12 payments
  4. PROCLAIM Neuromodulation $285 3 payments
  5. INTELLIS $236 3 payments
  6. SPRINT PNS System $193 2 payments
  7. Nalu Neurostimulation System $147 1 payment
  8. Infinion 16 $122 1 payment
  9. Evoke SCS $106 1 payment
  10. Senza $74 1 payment
  11. Other $142 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

427

Median for Anesthesiology: 322

Drug cost

$8,431

Median for Anesthesiology: $8,738

Branded share of claims

12.2%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 37 $1,946
Gabapentin Generic 100 $1,750
Lidocaine Generic 21 $1,201
Pregabalin Generic 49 $812
Duloxetine Hcl Generic 73 $701
Tizanidine Hcl Generic 25 $642
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 40 $474
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $431
Oxycodone Hcl Generic 24 $213
Tramadol Hcl Generic 20 $126

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$40,142

Medicare's payments for the services billed

Medicare patients

234

Average age 72

Services billed

769

132 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 62%
Depression 32%
Diabetes 30%
Ischemic heart disease 27%
Chronic kidney disease 27%
Cancer 23%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

50 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record